文献速递生殖医学

乳腺癌诊断不影响卵巢刺激反应

Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
PubMed 文献 · Hum Reprod · 2017-01-01

这项回顾性队列分析纳入2009至2015年间589例接受卵巢刺激进行生育力保存的患者,其中新诊断乳腺癌191例、择期生育力保存398例。结果显示两组基础窦卵泡计数及获卵数相似,但来曲唑使用与成熟率降低相关。作者认为乳腺癌诊断不影响卵巢刺激反应,应告知患者其反应与择期卵母细胞冷冻保存者相似。

要点

  • 乳腺癌患者与择期生育力保存者的基础窦卵泡计数相似(15.4±10.4 vs 15.4±10.0,P=NS)。
  • 两组获卵总数和成熟卵母细胞数相似,校正年龄、BMI和促性腺激素总剂量后仍相似。
  • 来曲唑使用与成熟率降低相关(0.71±0.01 vs 0.77±0.01,P<0.001),但成熟卵母细胞产出比相似。

核心结论

  • 乳腺癌诊断不影响以窦卵泡计数或卵巢刺激结局衡量的性腺功能。
  • 乳腺癌患者接受生育力保存卵巢刺激的反应与择期卵母细胞冷冻保存者相似。

研究设计与样本

  • 回顾性队列分析,纳入2009至2015年间589例接受卵巢刺激进行生育力保存的患者。
  • 新诊断乳腺癌患者191例,择期生育力保存者398例,均在学术医疗中心接受拮抗剂方案卵巢刺激。
  • 雌激素敏感型乳腺癌患者使用芳香化酶抑制剂来曲唑。

主要发现

  • 乳腺癌组与对照组基础窦卵泡计数相似(15.4±10.4 vs 15.4±10.0,P=NS),按年龄分层后仍相似。
  • 两组获卵总数相似(19.4±0.9 vs 17.0±0.5,P=NS),成熟(MII)卵母细胞数相似(13.7±0.7 vs 13.2±0.4,P=NS),校正年龄、BMI和促性腺激素总剂量后仍相似。
  • 来曲唑使用与成熟率(MII/获卵总数)降低相关(0.71±0.01 vs 0.77±0.01,P<0.001)。
  • 成熟卵母细胞产出比(MII/AFC)相似(1.01±0.06 vs 0.93±0.03,P=NS)。

临床怎么用

  • 作者认为,应告知乳腺癌患者其生育力保存卵巢刺激反应与择期卵母细胞冷冻保存者相似。

局限性

  • 单中心设计可能影响普适性。
  • 缺乏后续胚胎和妊娠数据是固有缺陷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does a breast cancer diagnosis impact ovarian function in the setting of fertility preservation? SUMMARY ANSWER: Ovarian reserve and ovarian stimulation outcomes are similar in patients with a new diagnosis of breast cancer and patients undergoing elective fertility preservation. WHAT IS KNOWN ALREADY: Prior studies, with small study populations, lack of controlling for individual differences in ovarian reserve and infertile controls, have reported conflicting outcomes for cancer patients undergoing ovarian stimulation for fertility preservation. STUDY DESIGN, SIZE, DURATION: This retrospective cohort analysis included 589 patients undergoing ovarian stimulation for fertility preservation between 2009 and 2015. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women with a recent breast cancer diagnosis (n = 191) and women desiring elective fertility preservation (n = 398) underwent ovarian stimulation with an antagonist protocol at an academic medical center. The aromatase inhibitor letrozole was administered to breast cancer patients with estrogen-sensitive disease. MAIN RESULTS AND THE ROLE OF CHANCE: Baseline antral follicle count (AFC) was not different between the breast cancer patients and controls (15.4 ± 10.4 [mean ± SD] vs 15.4 ± 10.0, P = NS), even after categorization by age. Total (19.4 ± 0.9 [mean ± SEM] vs 17.0 ± 0.5, P = NS) and mature (MII) oocytes retrieved (13.7 ± 0.7 vs 13.2 ± 0.4, P = NS), adjusted for age, BMI and total gonadotropin dose, were also similar between the two groups. Letrozole use was associated with a decreased maturity rate (MII/total oocytes retrieved) compared to elective cryopreservation (0.71 ± 0.01 vs 0.77 ± 0.01, P < 0.001), although the mature oocyte yield [MII/AFC] was comparable (1.01 ± 0.06 vs 0.93 ± 0.03, P = NS). LIMITATIONS, REASONS FOR CAUTION: The single center design may impact generalizability. Additionally, the lack of subsequent embryo and pregnancy data is an inherent weakness. WIDER IMPLICATIONS OF THE FINDINGS: In females, a breast cancer diagnosis does not impact gonadal function as measured by AFC or ovarian stimulation outcomes. Breast cancer patients should be counseled that their response to ovarian stimulation for fertility preservation is similar to that of patients undergoing elective oocyte cryopreservation. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Quinn MM, Cakmak H, Letourneau JM, et al. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017. PMID: 28122888. doi:10.1093/humrep/dew355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。